Fracture Patterns in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review of Recent Literature.

IF 4.3 2区医学 Current Osteoporosis Reports Pub Date : 2021-12-01 Epub Date: 2021-12-21 DOI:10.1007/s11914-021-00715-6

V Van Hulten, Nicklas Rasmussen, J H M Driessen, A M Burden, A Kvist, J P van den Bergh

{"title":"Fracture Patterns in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review of Recent Literature.","authors":"V Van Hulten, Nicklas Rasmussen, J H M Driessen, A M Burden, A Kvist, J P van den Bergh","doi":"10.1007/s11914-021-00715-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: In this narrative review, we have summarized the literature on fracture risk in T1DM and T2DM with a special focus on fracture site, time patterns, glucose-lowering drugs, and micro- and macrovascular complications.Recent findings: T1DM and T2DM were associated with an overall increased fracture risk, with preferent locations at the hip, vertebrae, humerus, and ankle in T1DM and at the hip, vertebrae, and likely humerus, distal forearm, and foot in T2DM. Fracture risk was higher with longer diabetes duration and the presence of micro- and macrovascular complications. In T2DM, fracture risk was higher with use of insulin, sulfonylurea, and thiazolidinediones and lower with metformin use. The increased fracture risk in T1DM and T2DM concerns specific fracture sites, and is higher in subjects with longer diabetes duration, vascular complications, and in T2DM with the use of specific glucose-lowering medication.","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"19 6","pages":"644-655"},"PeriodicalIF":4.3000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716348/pdf/","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Osteoporosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11914-021-00715-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 12

Abstract

Purpose of review: In this narrative review, we have summarized the literature on fracture risk in T1DM and T2DM with a special focus on fracture site, time patterns, glucose-lowering drugs, and micro- and macrovascular complications.

Recent findings: T1DM and T2DM were associated with an overall increased fracture risk, with preferent locations at the hip, vertebrae, humerus, and ankle in T1DM and at the hip, vertebrae, and likely humerus, distal forearm, and foot in T2DM. Fracture risk was higher with longer diabetes duration and the presence of micro- and macrovascular complications. In T2DM, fracture risk was higher with use of insulin, sulfonylurea, and thiazolidinediones and lower with metformin use. The increased fracture risk in T1DM and T2DM concerns specific fracture sites, and is higher in subjects with longer diabetes duration, vascular complications, and in T2DM with the use of specific glucose-lowering medication.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

1型和2型糖尿病的骨折模式:近期文献综述

综述目的:在这篇叙述性综述中，我们总结了关于T1DM和T2DM骨折风险的文献，特别关注骨折部位、时间模式、降糖药物以及微血管和大血管并发症。最近的研究发现:T1DM和T2DM与骨折风险的总体增加有关，T1DM患者更倾向于发生在髋部、椎骨、肱骨和踝关节，T2DM患者更倾向于发生在髋部、椎骨、可能发生在肱骨、前臂远端和足部。糖尿病病程越长，出现微血管和大血管并发症的患者骨折风险越高。在T2DM患者中，使用胰岛素、磺脲类药物和噻唑烷二酮类药物的骨折风险较高，而使用二甲双胍的骨折风险较低。T1DM和T2DM患者骨折风险的增加与特定骨折部位有关，在糖尿病病程较长、血管并发症和使用特定降糖药物的T2DM患者中骨折风险更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Osteoporosis Reports ENDOCRINOLOGY & METABOLISM-

CiteScore

8.40

自引率

2.30%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of osteoporosis. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and future therapeutics, epidemiology and pathophysiology, and evaluation and management. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.